Abstract & Overview
Dear Editor, We write in response to the growing clinical challenge of managing subclinical hypothyroidism (SCH) in older adults – a topic of considerable practical relevance yet persistent controversy. Defined biochemically by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine, SCH affects approximately 5%–10% of elderly subjects, especially elderly women.[1] A key clinical concern is the use of standard TSH reference ranges (0.4–4.5 mIU/L) in elderly patients, which may not be appropriate for this age group. TSH levels rise physiologically with age, even in healthy individuals without thyroid disease. The French Endocrine Society and India’s Indian Council of Medical Research guidelines now advocate age-adjusted thresholds (e.g., TSH ≤7 mIU/L for 70-year-olds and ≤8 mIU/L for 80-year-olds).[2,3] Applying standard ranges to this population may lead to overdiagnosis, resulting in unnecessary treatment, increased monitoring costs, and potential adverse effects from inappropriate levothyroxine therapy. The natural history of mild SCH (TSH: 4.5–10 mIU/L) further supports a watchful approach. Studies demonstrate that approximately 57%–61% of cases spontaneously normalize within 1–3 years, particularly in antibody-negative individuals.[4,5] Furthermore, transient TSH elevations may arise from nonautoimmune (non-Hashimoto’s) thyroiditis – such as subacute or silent thyroiditis – where the underlying inflammation resolves spontaneously, and treatment is generally not required.[6] Meanwhile, associations between SCH and adverse cardiovascular or cognitive outcomes, well-established in younger cohorts, appear substantially attenuated in patients over 70 years. The landmark TRUST trial reinforced this, finding no significant quality-of-life benefit from levothyroxine in elderly SCH patients.[7] Current evidence supports reserving treatment for elderly patients with TSH ≥10 mIU/L, overt hypothyroid symptoms, or positive anti-thyroid peroxidase antibodies.[8,9] When levothyroxine is initiated, low starting doses (12.5–25 μg/day), gradual titration, and higher target TSH levels (4–6 mIU/L) are recommended to minimize risks of iatrogenic thyrotoxicosis, atrial fibrillation, and accelerated bone loss.[9] In conclusion, optimal management of SCH in the elderly requires individualized, patient-centered decision-making that incorporates age-specific TSH reference ranges, comorbidity burden, functional status, and realistic assessment of treatment benefit. Adopting a conservative approach for most elderly patients with mild TSH elevation represents not therapeutic nihilism, but evidence-based care tailored to a unique and vulnerable population. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.